Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors is fully-enrolled and on track to yield topline data in early Q4 2025 SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) - ...

However, when it was dismantled in 2014, critics saw the move as a belated course correction—one that, in their view, should ...